quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·63d
PRRelease
Alnylam Pharmaceuticals Inc. logo
Denali Therapeutics Inc. logo
Wave Life Sciences Ltd. logo

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

ALNY· Alnylam Pharmaceuticals Inc.DNLI· Denali Therapeutics Inc.WVE· Wave Life Sciences Ltd.
Health Care
Original source

Companies

  • ALNY
    Alnylam Pharmaceuticals Inc.
    Health Care
  • DNLI
    Denali Therapeutics Inc.
    Health Care
  • WVE
    Wave Life Sciences Ltd.
    Health Care

Recent analyst ratings

  • Mar 26DNLIUpdateH.C. Wainwright$42.00
  • Mar 16ALNYUpdateJefferies$330.00
  • Feb 24DNLIUpdateWolfe Research-
  • Feb 5WVEUpdateBofA Securities$38.00
  • Jan 28ALNYUpdateBarclays$527.00
  • Jan 7ALNYUpdateOppenheimer$500.00

Related

  • PR1d
    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
  • PR1d
    Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
  • INSIDER2d
    Amendment: SEC Form 3 filed by new insider Chin Peter Scott
  • SEC2d
    SEC Form DEFA14A filed by Wave Life Sciences Ltd.
  • SEC2d
    SEC Form 8-K filed by Wave Life Sciences Ltd.
  • SEC2d
    SEC Form DEFA14A filed by Denali Therapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Denali Therapeutics Inc.
  • PR2d
    Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022